CoChat

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

Open access
Joseph, James D, Darimont, Beatrice, Zhou, Wei, Arrazate, Alfonso, Young, Amy, Ingalla, Ellen, Walter, Kimberly, Blake, Robert A, Nonomiya, Jim, Guan, Zhengyu, Kategaya, Lorna, Govek, Steven P, Lai, Andiliy G, Kahraman, Mehmet, Brigham, Dan, Sensintaffar, John, Lu, Nhin, Shao, Gang, Qian, Jing, Grillot, Kate, Moon, Michael, Prudente, Rene, Bischoff, Eric, Lee, Kyoung-Jin, Bonnefous, Celine, Douglas, Karensa L, Julien, Jackaline D, Nagasawa, Johnny Y, Aparicio, Anna, Kaufman, Josh, Haley, Benjamin, Giltnane, Jennifer M, Wertz, Ingrid E, Lackner, Mark R, Nannini, Michelle A, Sampath, Deepak, Schwarz, Luis, Manning, Henry Charles, Tantawy, Mohammed Noor, Arteaga, Carlos L, Heyman, Richard A, Rix, Peter J, Friedman, Lori, Smith, Nicholas D, Metcalfe, Ciara, Hager, Jeffrey H · 2016 · eLife
Cited by 118

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need for improved therapeutic strategies. The recent discovery of prevalent ESR1 mutations in relapsed tumors underscores a sustained reliance of advanced tumors on ERα signaling, and provides a strong rationale for continued targeting of ERα. Here we describe GDC-0810, a novel, non-steroidal, orally bioavailable selective ER downregulator (SERD), which was identified by prospectively optimizing ERα degradation, antagonism and pharmacokinetic properties. GDC-0810 induces a distinct ERα conformation, relative to that induced by currently approved therapeutics, suggesting a unique mechanism of action. GDC-0810 has robust in vitro and in vivo activity against a variety of human breast cancer cell lines and patient derived xenografts, including a tamoxifen-resistant model and those that harbor ERα mutations. GDC-0810 is currently being evaluated in Phase II clinical studies in women with ER+ breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7554/elife.15828

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 118

Metadata

Authors
Joseph, J. D., Darimont, B., Zhou, W., Arrazate, A., Young, A., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., Kategaya, L., Govek, S. P., Lai, A. G., Kahraman, M., Brigham, D., Sensintaffar, J., Lu, N., Shao, G., Qian, J., Grillot, K., Moon, M., Prudente, R., Bischoff, E., Lee, K.-J., Bonnefous, C., Douglas, K. L., Julien, J. D., Nagasawa, J. Y., Aparicio, A., Kaufman, J., Haley, B., Giltnane, J. M., Wertz, I. E., Lackner, M. R., Nannini, M. A., Sampath, D., Schwarz, L., Manning, H. C., Tantawy, M. N., Arteaga, C. L., Heyman, R. A., Rix, P. J., Friedman, L., Smith, N. D., Metcalfe, C., & Hager, J. H.
Venue
eLife
Published
2016-07-13
Volume
5
ISSN
2050-084X (ISSN-L)
OpenAlex
W2468302041
Cited by
118
References
6
FWCI
9.30
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. https://app.cochat.ai/papers/10.7554/elife.15828
The paper
Joseph, J. D., Darimont, B., Zhou, W., Arrazate, A., Young, A., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., Kategaya, L., Govek, S. P., Lai, A. G., Kahraman, M., Brigham, D., Sensintaffar, J., Lu, N., Shao, G., Qian, J., . . . Hager, J. H. (2016). The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. eLife. https://doi.org/10.7554/elife.15828

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.